---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009695"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:53:37.103467+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO Health sells BioReference clinical diagnostics business to LabCorp for ~$237.5M

## Summary
- Asset Purchase Agreement with LabCorp for $237.5M cash, excluding oncology/urology and NY/NJ operations.
- Transaction includes transfer of certain BioReference employees; no financing condition required.
- Closing subject to HSR clearance and customary conditions; 180-day outside date with potential extensions.
- Termination fee payable by LabCorp in certain circumstances if regulatory clearance fails.
- OPKO retains nationwide oncology/urology and all NY/NJ operations post-closing.

## SEC filing metadata
- accession: 0001437749-24-009695
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/0001437749-24-009695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009695
- JSON: https://secwatch.observer/filing/0001437749-24-009695.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009695.txt

## Key facts
- Material Agreements
  OPKO HEALTH, INC. entered into Asset Purchase Agreement with Laboratory Corporation of America Holdings valued at approximately $237,500,000 in cash (effective 2024-03-27).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Laboratory Corporation of America Holdings
  - Value: approximately $237,500,000 in cash
  - Effective: 2024-03-27
  source text: On March 27, 2024, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/0001437749-24-009695-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.